

Liste der bewilligten Forschungsprojekte 2024 (1. Semester) *Liste des projets de recherche acceptés en 2024 (1^{er} semestre)*

Im [Forschungsportal](#) finden Sie Informationen zu allen Projekten, die die Stiftung Krebsforschung Schweiz und ihre Partnerorganisation Krebsliga Schweiz seit dem Jahr 2005 gefördert haben.

Dans le [portail de recherche](#), vous trouverez les informations sur tous les projets soutenus par la fondation Recherche suisse contre le cancer et son organisation partenaire, la Ligue suisse contre le cancer, depuis 2005.

Basic research

Basler Konrad | Investigating the similarities and differences between left- and right-sided colon cancer: a metastasis focus

Institut für Molekulare Biologie, Universität Zürich (UZH), Zürich

CHF 207 500 | 18 months | [KFS-6031-02-2024](#)

Becher Burkhard | Targeting IL-23R on tumour-infiltrating Tregs for cancer immunotherapy

Institute of Experimental Immunology, University of Zurich, Zürich

CHF 351 578 | 36 months | [KFS-6022-02-2024](#)

Beerenwinkel Niko | Profiling tumour evolution in ovarian cancer for precision oncology

Department of Biosystems Science and Engineering, ETH Zürich, Basel

CHF 373 051 | 36 months | [KFS-6058-02-2024](#)

Coukos George | Laboratory evolution of cell states for next generation T cell cancer immunotherapy

Department of Oncology, Centre hospitalier universitaire vaudois (CHUV), Lausanne

CHF 358 143 | 48 months | [KFS-6060-02-2024](#)

De Palma Michele | Rewiring lung cancer immunity with engineered dendritic cell progenitors

Swiss Institute for Experimental Cancer Research (ISREC), EPF de Lausanne, Lausanne

CHF 366 980 | 36 months | [KFS-6045-02-2024](#)

Fernandez Gonzalez Santiago | Influence of the lymphatic versus hematogenous dissemination of B cell lymphoma in the immune response

Infection and Immunity, Institute for Research in Biomedicine (IRB), Bellinzona

CHF 346 738 | 48 months | [KFS-6092-02-2024](#)

Gönczy Pierre | Uncovering centriole number control mechanisms in health and cancer

SV ISREC UPGON, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne 15

CHF 373 980 | 36 months | [KFS-6018-02-2024](#)

Jourdain Alexis | Blocking nucleoside catabolism to starve tumours
Immunobiology (formerly Biochemistry), Université de Lausanne (UNIL), Epalinges
CHF 375 000 | 48 months | [KFS-6029-02-2024](#)

Riek Roland | A new strategy to treat MAPK inhibitor resistant melanomas using the amyloid fold.
Departement Chemie und Angewandte Biowissenschaften (D-CHAB), ETH Zürich, Zürich
CHF 374 640 | 48 months | [KFS-6068-02-2024](#)

Tamburini Jerome | Targeting iron metabolism to eliminate quiescent leukemic stem cells in acute myeloid leukaemia
Medical specialities, Université de Genève (UNIGE), Genève
CHF 369 619 | 36 months | [KFS-6032-02-2024](#)

Weller Michael | Vortioxetine against glioblastoma: drug repurposing meets cancer neuroscience
Department of Neurology, University Hospital Zurich, Zurich
CHF 341 833 | 36 months | [KFS-6084-02-2024](#)

Epidemiological research

Katapodi Maria | CASCADE III: Designing risk-stratified models of survivorship care for HBOC and Lynch syndrome families
Clinical Research, Faculty of Medicine, Universität Basel, Basel
CHF 374 999 | 36 months | [KFS-6088-02-2024](#)

Rothermundt Christian | Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)
Bereich Onkologie / Hämatologie, Kantonsspital St. Gallen (KSSG), St.Gallen
CHF 217 760 | 48 months | [KFS-6034-02-2024](#)

Schindera Christina | Prospective multicentre cohort study of cardiac dysfunction in childhood cancer survivors: extension of the CardioOnco Study
University Children's Hospital Basel, Universität Basel, Basel
CHF 374 409 | 36 months | [KFS-6096-02-2024](#)

Psychosocial research

Sommer Grit | Exploring trends of health-related quality of life after childhood cancer and its drivers/determinants: A longitudinal study
Institute of Social and Preventive Medicine, University of Bern, Bern
CHF 366 775 | 36 months | [KFS-6105-02-2024](#)

Clinical Research – laboratory-oriented

Moeckli Raphaël | FLIRT: FLASH irradiation treatment planning to facilitate and optimize glioblastoma treatments with very-high energy electron FLASH radiation therapy
Institut de Radiophysique, Centre hospitalier universitaire vaudois (CHUV), Lausanne
CHF 251 143 | 48 months | [KFS-6020-02-2024](#)

Vassella Erik | Overcoming resistance to temozolomide and immunotherapy by targeting the nonsense-mediated mRNA decay pathway in glioblastoma tumours
Institute of Tissue Medicine and Pathology, Universität Bern, Bern
CHF 349 842 | 48 months | [KFS-6061-02-2024](#)

Wirsching Hans-Georg | Radiation-Associated Meningioma Molecular Profiling to Inform Targeted Therapies (RAMPIT)
Neurology, UniversitätsSpital Zürich (USZ), Zürich
CHF 371 188 | 48 months | [KFS-6103-02-2024](#)

Clinical Research – patient-oriented

Bösch Maximilian | Fibre-Boost: A multicentre, 2:1 randomized, controlled trial to study the effects of a high-fibre dietary intervention on ctDNA clearance and the microbial and immunological landscape in immune checkpoint blockade-treated advanced non-small cell lung cancer
Lung Center, Kantonsspital St. Gallen (KSSG), St.Gallen
CHF 374 950 | 36 months | [KFS-6039-02-2024](#)

Gotta Verena | Prospective pharmacologic characterization of a novel cytomegalovirus-infection prophylaxis (Letermovir) in paediatric hematopoietic cell transplantation patients using endogenous Coproporphyrin (LetPeCo)
Pädiatrische Klinische Pharmazie / Pediatric Pharmacology and Pharmacometrics, Universitäts-Kinderspital beider Basel UKBB, Basel
CHF 167 580 | 42 months | [KFS-6041-02-2024](#)

Heinzelmann-Schwarz Viola | Continuation of MATAO-Trial “Maintenance therapy with aromatase inhibitor in epithelial ovarian cancer: a phase III randomized double-blind placebo-controlled trial”
Gynecological Oncology, Universitätsspital Basel, Basel
CHF 357 846 | 36 months | [KFS-6066-02-2024](#)

Petignat Patrick | Validation of AI-assisted digital telecytology for the triage of HPV-positive women in a same-day ‘Test-triage-treat’ strategy in Cameroon
Unité d'oncogynécologie chirurgicale, Hôpitaux universitaires de Genève (HUG), Genève
CHF 375 000 | 36 months | [KFS-6044-02-2024](#)

Wenning Anna Silvia | TOPANC Trial: Survival after TOfal versus partial PANCreaticoduodenectomy for adenocarcinoma of the pancreatic head, distal cholangiocarcinoma and ampullary cancer: a prospective multi-centric randomized controlled trial.
Department for Visceral Surgery and Medicine, Inselspital Bern, Bern
CHF 365 960 | 48 months | [KFS-6043-02-2024](#)

Health Services Research

Cathomas Richard | Oncological and functional follow-up after cystectomy and trimodal therapy (INFORMATORY)

Onkologie, Kantonsspital Graubünden, Chur

CHF 313 777 | 48 months | [KFS-6065-02-2024](#)

Cobos Munoz Daniel | Enhancing palliative care in Lao PDR: addressing the unmet needs

Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil

CHF 276 606 | 36 months | [KFS-6082-02-2024](#)

Maessen Maud | The impact of care goals on costs of inpatient palliative care patients with cancer. Have we been comparing apples and oranges?

University centre of palliative care, Inselspital Bern, Bern

CHF 105 680 | 18 months | [KFS-6062-02-2024](#)

Tolotti Angela | Advanced Practice Nursing in an oncology palliative care setting and its effects on patient autonomy, engagement and interprofessional collaboration: an implementation mixed-method pre-post study

Nursing research and development unit, Istituto oncologico della Svizzera italiana (IOSI), Bellinzona

CHF 193 929 | 36 months | [KFS-6023-02-2024](#)

Fellowships

Peres Tobias | Real world data of Nivolumab/Relatlimab in patients with melanoma brain metastasis

Medical Oncology / Hematology, Kantonsspital St. Gallen (KSSG), St. Gallen

CHF 62 600 | 12 months | [KFS-6101-02-2024](#)

Thavayogarah Tharshika | Identifying the role of WRN in clonal haematopoiesis

Department of Hematology and Oncology, UniversitätsSpital Zürich (USZ), Zürich

CHF 126 000 | 24 months | [KFS-6067-02-2024](#)